This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MGC Pharmaceuticals Valuation

Is MXCDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MXCDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MXCDA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MXCDA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MXCDA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MXCDA. This is calculated by dividing MXCDA's market cap by their current preferred multiple.
What is MXCDA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AU$2.46m

MXCDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.3x
Enterprise Value/EBITDA	-0.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MXCDA's PS Ratio compare to its peers?

The above table shows the PS ratio for MXCDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.2x
WFL Wellfully	0.9x	n/a	AU$1.5m
AGH Althea Group Holdings	0.6x	n/a	AU$18.8m
CGB Cann Global	9.7x	n/a	AU$5.4m
RNO Rhinomed	1.4x	n/a	AU$11.5m
MXCDA MGC Pharmaceuticals	0.7x	n/a	AU$2.5m

Price-To-Sales vs Peers: MXCDA is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (3.5x).

Price to Earnings Ratio vs Industry

How does MXCDA's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	55.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	55.0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: MXCDA is good value based on its Price-To-Sales Ratio (0.7x) compared to the Australian Pharmaceuticals industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is MXCDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MXCDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MXCDA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.